Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07516093 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | PHASE3 | NOT YET_RECRUITING | 620 | — | — | Jun 1, 2026 | Jun 1, 2032 | Apr 8, 2026 | - | — |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | PHASE1 | NOT YET_RECRUITING | 150 | — | — | May 1, 2026 | May 1, 2033 | Apr 13, 2026 | - | — |
Time from randomization to disease progression or death due to any cause, whichever is earlier
| Arm | Type | Description |
|---|---|---|
| Arm A: NX-5948 | EXPERIMENTAL | - |
| Arm B: Pirtobrutinib | EXPERIMENTAL | - |
| NX-5948 + venetoclax | EXPERIMENTAL | - |
| NX-5948 + venetoclax + rituximab | EXPERIMENTAL | - |
| NX-5948 + venetoclax + obinutuzumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NX-5948 | DRUG | Administered orally once daily |
| Pirtobrutinib | DRUG | Administered orally once daily per prescribing information |
| venetoclax | DRUG | Administered orally once daily as a tablet per prescribing information |
| rituximab | DRUG | Administered as an intravenous (IV) infusion per prescribing information |
| obinutuzumab | DRUG | Administered as an IV infusion per prescribing information |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Adequate organ and bone marrow function * Confirmed diagnosis of CLL/SLL that meets iwCLL 2018 criteria for diagnosis and systemic treatment * Received at least one prior line of therapy for CLL/SLL t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Soligenix, Inc. | SNGX | 1 | PHASE3 | Hypericin |
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | — | Undisclosed |